SFF
While the rapid development of COVID-19 vaccines helped to wind down the pandemic, it also brought to light the many challenges involved in ramping up the production of injectables that must be made in sterile, aseptic environments. Several companies struggled to compress what’s normally a year-long process into a matter of months.
Pitfalls can be avoided, however, by improving planning processes and adopting new technologies to streamline manufacturing. As manufacturers expand beyond small molecules and first-generation biologics into more complex molecules such as gene therapies and mRNA vaccines, they’ll need to embrace these new tools.
To read our case study please complete your details below: